Adverse Events and Outcomes for Second-Line Liver Cancer Therapies

A 2026 retrospective study by Chinatsu Nishioka compares second-line therapies for unresectable hepatocellular carcinoma. The dataset contains real-world data from 81 patients treated with either durvalumab plus tremelimumab or lenvatinib after first-line atezolizumab plus bevacizumab. It includes measures of tumor response, progression-free survival, overall survival, adverse events, and albumin–bilirubin score changes.

Use Cases

• Compare progression-free survival (PFS) and overall survival (OS) between two second-line treatment regimens.
• Analyze the frequency and severity of adverse events (AEs) associated with different therapies.
• Assess changes in liver function via albumin–bilirubin (ALBI) scores over a 4-week period.
• Evaluate objective response and disease control rates using RECIST criteria.

Strengths

• Includes specific patient counts for each treatment group (Dur/Tre group n=14, Len group n=67).
• Reports concrete clinical metrics, including median PFS (1.7 vs. 4.2 months) and median OS (5.3 vs. 14.0 months).
• Provides detailed adverse event rates (Grade ≥3 AEs: 70.1% vs. 21.4%).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 5.5 KB, indicating limited scope.

Provenance

Source

figshare, author Chinatsu Nishioka.

Collection Method

Retrospective analysis of a prospectively registered observational cohort.

Time Range

null

Freshness

Last updated 2026-05-07 18:00:14; freshness should be verified.

Geography

null